Belgium’s Galapagos NV has acquired assets in the field of drug discovery from Sareum Holdings Plc which will enable it to quickly identify promising new small molecule drugs. The acquisition, for £553,000, will give Galapagos all of Sareum’s contracts relating to structure-based drug discovery.
